How do you define "low-volume" intermediate risk prostate cancer that is appropriate for brachytherapy alone?

For prostate cancer the use of PSA, T-stage, and Gleason score have been used to create multiple different risk stratification schemes. That of @Dr. First Last, the NCCN, and the AJCC are all very similar. In addition, other methods such as the Memorial Sloan Kettering nomograms and the CAPRA score ...

@Dr. First Last has summed up the most relevant empiric evidence available to date. This provides the assurance that favorable-interm risk prostate cancers with good urinary function are generally good candidates for brachytherapy monotherapy. Yet, with regards to patients with more aggressive GS 7 ...

I would just say that probably any increase in risk factors increases risk. Perhaps even "secondary" gleason score, meaning if you had only a small core of G3+4 but the rest G3+3 your secondary score is 6 or if G4+3 but you had another G3+4 then your secondary is 3+4.

Also number of cores + is a mov...